SCHEMBL1170158

SCHEMBL1170158

CCCCN(Cc1ccc(CN(CCCC)C(=N)NC(=N)Nc2ccc(Cl)cc2)cc1)C(=N)NC(=N)Nc1ccc(C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.44
TP53 P04637 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HDAC6 Q9UBN7 4/20 0.40
HDAC3 O15379 3/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC2 Q92769 3/20 0.40
HDAC4 P56524 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC9 Q9UKV0 2/20 0.40
HDAC5 Q9UQL6 2/20 0.40
LMNA P02545 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1171548 0.95 CNR2 (0.45) CNR2GAAMAPTHDAC6HDAC3
SCHEMBL10083469 0.94 HDAC6 (0.43) CNR2HDAC6HDAC3HDAC1HDAC2
SCHEMBL13953641 0.93 CNR2 (0.39) CNR2TP53NPC1RAB9AGAA
SCHEMBL13528906 0.93 TP53 (0.47) CNR2TP53NPC1RAB9AGAA
SCHEMBL1108183 0.88 CNR2 (0.40) CNR2NPC1RAB9AGAAMAPT
SCHEMBL8963242 0.87 CNR2 (0.39) CNR2GAAMAPTHDAC6HDAC3
SCHEMBL13523186 0.84 CNR2 (0.37) CNR2GAAMAPTHDAC6HDAC3
SCHEMBL1176293 0.83 HDAC6 (0.54) CNR2HDAC6HDAC3HDAC1HDAC2
SCHEMBL14703480 0.82 SIGMAR1 (0.43) CNR2HDAC6HDAC3HDAC1HDAC2
SCHEMBL13521679 0.81 SMN1; SMN2 (0.39) GAALMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188068-B2 Bridged polycyclic compound based compositions for coating oral surfaces in pets ALLACCEM, INC. (US) 2012-05-29 US disclosed
US-8153618-B2 Bridged polycyclic compound based compositions for topical applications for pets ALLACCEM, INC. (US) 2012-04-10 US disclosed
US-20100016270-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS ALLACCEM, INC. 2010-01-21 US disclosed
US-20090069435-A1 Bridged polycyclic compound based compositions for topical applications for pets ALLACCEM, INC. 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069435-A1 Bridged polycyclic compound based compositions for topical applications for pets OTC, SLC16A8, SLC16A7 CNR2 474/4885TP53 804/4885NPC1 657/4885
US-20100016270-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS PCSK9, HMGCR, CETP CNR2 850/4885TP53 4241/4885NPC1 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.